Rarity PBC Raises $4.6 Million Seed Financing to Advance Gene Therapy for ADA-SCID, led by Steve Oliveira from Nemean Asset Management.

Oct 29, 2025•5 days ago

Amount Raised

$4.6 Million

Round Type

seed

Los AngelesBiotechnologyHealth Care

Investors

Nemean Asset ManagementSteve Oliveira

Description

Rarity PBC has successfully closed a $4.6 million seed financing round aimed at accelerating the development of their gene therapy for ADA-SCID. The funding was led by biotech investor Steve Oliveira. Proceeds will support efforts towards establishing commercial-grade manufacturing and gaining FDA approval. Rarity aims to ensure all children with ADA-SCID can access the therapy.

Company Information

Company

Rarity PBC

Location

Los Angeles, California, United States

About

Rarity PBC is a Public Benefit Corporation focused on expanding access to transformative gene therapies for rare diseases. The company is dedicated to developing a one-time autologous hematopoietic stem cell gene therapy for adenosine deaminase severe combined immunodeficiency (ADA-SCID). Rarity aims to merge clinical validation with a public benefit mandate to enhance treatment access for patients. The team collaborates closely with researchers from UCLA to bring innovative therapies to market.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns